A R&D company focusing on iPSC-CAR-NK cell therapy product
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.09.2022 | Series A | $50M | - |
Mentions in press and media 3
| Date | Title | Description |
| 04.09.2022 | Neukio Biotherapeutics Closes $50M Series A-1 Financing | Neukio Biotherapeutics, a Chinese company committed to developing cell therapy products, raised $50M in Series A-1 funding.
The round was led by CD Capital, with participation from Alwin Capital, Surplus Capital, Lilly Asia Ventures, Sherpa... |
| 03.09.2022 | Chinese startup Neukio Biotherapeutics closes its Series A-1 financing at USD 50 million | Shanghai, China-based company that develops novel cell therapy, Neukio Biotherapeutics, closed its Series A1 financing. The company announced the closure of the round on September 2, 2022. Neukio Biotherapeutics closed the Series A1 round a... |
| 02.09.2022 | Neukio Biotherapeutics completed Series A-1 financing, to accelerate discovery and development of next generation cell therapy products | SHANGHAI, Sept. 2, 2022 /PRNewswire/ -- Neukio Biotherapeutics, a company committed to developing novel cell therapy products, announces it has closed $50 million in a Series A-1 funding round. The investment round was led by CD Capital, wi... |
Reviews 0
